GCM
SMMT icon

Graham Capital Management’s Summit Therapeutics SMMT Stock Holding History

Graham Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,961
Closed -$78.5K – 1336
2024
Q1 		$78.5K Buy
+18,961
New +$75.4K ﹤0.01% 989

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Management's SMMT Position: Q2 2024 in Review

Graham Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 18,961 shares — an estimated $78.5K sold.

Graham Capital Management first reported a position in SMMT in Q1 2024 and held it in 1 quarter. The position peaked at $78.5K in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • Graham Capital Management reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Graham Capital Management sold 18,961 Summit Therapeutics shares in Q2 2024, an estimated $78.5K.
  • Graham Capital Management first reported a position in Summit Therapeutics in Q1 2024 and held it in 1 quarter.
  • Graham Capital Management's Summit Therapeutics position peaked at $78.5K in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.